Product Name
CYP1B1, siRNA
Full Product Name
CYP1B1 siRNA (Rat)
Product Synonym Names
Cytochrome P450 1B1; CYPIB1; Cytochrome P450RAP
Product Gene Name
CYP1B1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q64678
Specificity
CYP1B1 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat CYP1B1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CYP1B1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CYP1B1 sirna
siRNA to inhibit CYP1B1 expression using RNA interference
Applications Tested/Suitable for CYP1B1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CYP1B1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_037072.1
[Other Products]
NCBI GenBank Nucleotide #
NM_012940.2
[Other Products]
UniProt Primary Accession #
Q64678
[Other Products]
UniProt Related Accession #
Q64678[Other Products]
Molecular Weight
60,557 Da
NCBI Official Full Name
cytochrome P450 1B1
NCBI Official Synonym Full Names
cytochrome P450, family 1, subfamily b, polypeptide 1
NCBI Official Symbol
Cyp1b1??[Similar Products]
NCBI Protein Information
cytochrome P450 1B1
UniProt Protein Name
Cytochrome P450 1B1
UniProt Synonym Protein Names
CYPIB1; Cytochrome P450RAP
Protein Family
Cytochrome
UniProt Gene Name
Cyp1b1??[Similar Products]
UniProt Entry Name
CP1B1_RAT
NCBI Summary for CYP1B1
plays a role in polycyclic aromatic hydrocarbon metabolism in adrenal microsomes [RGD, Feb 2006]
UniProt Comments for CYP1B1
CYP1B1: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Defects in CYP1B1 are the cause of primary congenital glaucoma type 3A (GLC3A). GLC3A is an autosomal recessive form of primary congenital glaucoma (PCG). PCG is characterized by marked increase of intraocular pressure at birth or early childhood, large ocular globes (buphthalmos) and corneal edema. It results from developmental defects of the trabecular meshwork and anterior chamber angle of the eye that prevent adequate drainage of aqueous humor. Defects in CYP1B1 are a cause of primary open angle glaucoma (POAG). POAG is a complex and genetically heterogeneous ocular disorder characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. The disease is asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. In some cases, POAG shows digenic inheritance involving mutations in CYP1B1 and MYOC genes. Defects in CYP1B1 are a cause of Peters anomaly (PAN). Peters anomaly is a congenital defect of the anterior chamber of the eye. Belongs to the cytochrome P450 family.
Protein type: Membrane protein, peripheral; Endoplasmic reticulum; Oxidoreductase; Motility/polarity/chemotaxis; Xenobiotic Metabolism - metabolism by cytochrome P450; Amino Acid Metabolism - tryptophan; EC 1.14.14.1
Cellular Component: endoplasmic reticulum membrane; mitochondrion; intracellular membrane-bound organelle; nucleus
Molecular Function: oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen; iron ion binding; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; heme binding; oxidoreductase activity; monooxygenase activity
Biological Process: benzene and derivative metabolic process; steroid metabolic process; estrogen metabolic process; retinal metabolic process; collagen fibril organization; positive regulation of translation; positive regulation of apoptosis; dibenzo-p-dioxin metabolic process; response to arsenic; response to toxin; positive regulation of JAK-STAT cascade; positive regulation of smooth muscle cell migration; response to organic cyclic substance; response to estradiol stimulus; response to organic substance; negative regulation of cell proliferation; retinol metabolic process; arachidonic acid metabolic process; angiogenesis; nitric oxide biosynthetic process; cell adhesion; negative regulation of cell adhesion mediated by integrin; negative regulation of cell migration; response to nutrient; adrenal gland development; male gonad development; DNA modification; positive regulation of angiogenesis; inhibition of NF-kappaB transcription factor; response to steroid hormone stimulus; toxin metabolic process; xenobiotic metabolic process; blood vessel morphogenesis; aromatic compound metabolic process; endothelial cell migration; membrane lipid catabolic process; induction of apoptosis by oxidative stress; response to follicle-stimulating hormone stimulus
Research Articles on CYP1B1
1. The influence of dietary lipids on the ontogeny of XMEs was also evaluated. mRNA and protein levels of phase I (CYP1A1, CYP1A2, and CYP1B1) and phase II (NAD(P)H:quinone acceptor oxidoreductase 1 and GSTP1) enzymes were analyzed.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
